Evidence map›Paper›PMID 31540931›Full record

SynthesisClinical journal of the American Society of Nephrology : CJASN2019

Risk Factors for 1-Year Graft Loss After Kidney Transplantation: Systematic Review and Meta-Analysis.

Farid Foroutan, Erik Loewen Friesen, Kathryn Elizabeth Clark, Shahrzad Motaghi, Roman Zyla, Yung Lee, Rakhshan Kamran, Emir Ali, Mitch De Snoo, Ani Orchanian-Cheff and 4 more

Registry-linked trialAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Clinical journal of the American Society of Nephrology : CJASN, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04705402 (A Prospective, Randomized, Double Blinded, Placebo Control Trial to Evaluate Efficacy of Intravenous Mannitol Use During Cadaveric Kidney Transplantation Prior to Kidney Reperfusion), which is not on this map. Cited by 61 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04705402 naunknown statusnot on this mapstarted 2022, after this paper: background citation

A Prospective, Randomized, Double Blinded, Placebo Control Trial to Evaluate Efficacy of Intravenous Mannitol Use During Cadaveric Kidney Transplantation Prior to Kidney Reperfusion

TypeinterventionalSponsorRabin Medical CenterRan2022 to 2022Enrolled32ConditionsRenal DialysisArmsMannitol, Saline
3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Anti-obesity Pharmacotherapy for Transplant Recipients.Current atherosclerosis reports · 2026
    Review
  11. Article
  12. The obese transplant organ recipient: experimental and clinical evidence for tailored immunosuppression.Transplant international : official journal of the European Society for Organ Transplantation · 2026
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Farid ForoutanTed Rogers Centre for Heart Research, Multi-Organ Transplant Program, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.
Erik Loewen FriesenLibrary and Information Services, University Health Network, Toronto, Ontario, Canada.
Kathryn Elizabeth ClarkTed Rogers Centre for Heart Research, Multi-Organ Transplant Program, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.
Shahrzad MotaghiDepartment of Health Research Methods, Evidence, and Impact and.
Roman ZylaLibrary and Information Services, University Health Network, Toronto, Ontario, Canada.
Yung LeeDepartment of Health Research Methods, Evidence, and Impact and.
Rakhshan KamranDepartment of Health Research Methods, Evidence, and Impact and.
Emir AliDepartment of Health Research Methods, Evidence, and Impact and.
Mitch De SnooDepartment of Medicine, University of Toronto, Toronto, Ontario, Canada; and.
Ani Orchanian-CheffDepartment of Medicine, McMaster University, Hamilton, Ontario, Canada.ORCID 0000-0002-9943-2692
Christine RibicDepartment of Medicine, University of Toronto, Toronto, Ontario, Canada; and.
Darin J TreleavenDepartment of Medicine, University of Toronto, Toronto, Ontario, Canada; and.
Gordon GuyattDepartment of Health Research Methods, Evidence, and Impact and.
Maureen O MeadeDepartment of Health Research Methods, Evidence, and Impact and.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesWith expansion of the pool of kidney grafts, through the use of higher-risk donors, and increased attention to donor management strategies, the 1-year graft survival rate is subject to change. It is, therefore, useful to elucidate 1-year graft survival rates by dissecting the characteristics of the low-risk and high-risk kidney transplant cases. The objective of our study was to evaluate factors purported to influence the risk of 1-year graft loss in kidney transplant recipients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We searched bibliographic databases from 2000 to 2017 and included observational studies that measured the association between donor, recipient, the transplant operation, or early postoperative complications, and 1-year death-censored graft loss.

resultsWe identified 35 eligible primary studies, with 20 risk factors amenable to meta-analysis. Six factors were associated with graft loss, with moderate to high degree of certainty: donor age (hazard ratio [HR], 1.11 per 10-year increase; 95% confidence interval [95% CI], 1.04 to 1.18), extended criteria donors (HR, 1.35; 95% CI, 1.28 to 1.42), deceased donors (HR, 1.54; 95% CI, 1.32 to 1.82), number of HLA mismatches (HR, 1.08 per one mismatch increase; 95% CI, 1.07 to 1.09), recipient age (HR, 1.17 per 10-year increase; 95% CI, 1.09 to 1.25), and delayed graft function (HR, 1.89; 95% CI, 1.46 to 2.47) as risk factors for 1-year graft loss. Pooled analyses also excluded, with a high degree of certainty, any associations of cold ischemia time, recipient race, pretransplant body mass index, diabetes, and hypertension with 1-year graft loss.

conclusionsRecipient age, donor age, standard versus extended criteria donor, living versus deceased donor, HLA mismatch, and delayed graft function all predicted 1-year graft survival. The effect of each risk factor is small.

Indexed as

Graft SurvivalKidney TransplantationHumansRisk FactorsTime Factorsattentionbibliographic databasesbody mass indexchronic allograft failurecold ischemiadelayed graft functiondiabetes mellitusEpidemiology and outcomesgraft survivalHLA antigenshumanshypertensionkidney transplantationliving donorsrisk factorsTransplantationtransplant recipients

Identifiers

PMID31540931
PMCPMC6832056

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.